rs150390726
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_024675.4(PALB2):c.23C>T(p.Pro8Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000936 in 1,613,342 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PALB2 | NM_024675.4 | c.23C>T | p.Pro8Leu | missense_variant | 1/13 | ENST00000261584.9 | NP_078951.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PALB2 | ENST00000261584.9 | c.23C>T | p.Pro8Leu | missense_variant | 1/13 | 1 | NM_024675.4 | ENSP00000261584.4 |
Frequencies
GnomAD3 genomes AF: 0.000480 AC: 73AN: 152172Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.000125 AC: 31AN: 247906Hom.: 0 AF XY: 0.0000744 AC XY: 10AN XY: 134434
GnomAD4 exome AF: 0.0000534 AC: 78AN: 1461170Hom.: 0 Cov.: 31 AF XY: 0.0000468 AC XY: 34AN XY: 726856
GnomAD4 genome AF: 0.000480 AC: 73AN: 152172Hom.: 1 Cov.: 32 AF XY: 0.000525 AC XY: 39AN XY: 74344
ClinVar
Submissions by phenotype
not provided Benign:5
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 16, 2017 | Variant summary: The c.23C>T (p.Pro8Leu) in PALB2 gene is a missense change that involves a non-conserved nucleotide and 3/5 in silico tools predict deleterious outcome. The variant is located in the a coiled-coil domain of PALB2 required for RAD51- and BRCA1-binding, however no functional studies confirming deleterious effect of this change have been reported at the time of evaluation. The variant is present in the control population dataset of ExAC at a frequency of 0.0001801 (20/ 111058 chrs tested), predominantly in individuals of African descent (0.001817; 16/ 8808 chrs tested). The observed frequencies exceed the maximum expected allele frequency for a pathogenic variant of 0.000156, suggesting it is may be an ethnic-specific functional polymorphism. The variant has been reported in BrC pt without strong evidence for causality. The variant is cited as VUS/Likely Benign by reputable databases/clinical laboratories without evidence to independently evaluate. Taking together, the variant was classified as Likely Benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Feb 27, 2019 | - - |
Likely benign, no assertion criteria provided | curation | Leiden Open Variation Database | May 13, 2019 | Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitters to LOVD: Marc Tischkowitz, Melissa DeRycke. - |
Benign, criteria provided, single submitter | clinical testing | Mendelics | Dec 13, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 31, 2020 | Published functional studies demonstrate moderate PARPi sensitivity, moderate interaction with BRCA1, cellular localization similar to wild type, normal response to DNA damage, reduced RAD51 foci formation, and normal or decreased HDR activity (Rodrigue 2019, Wiltshire 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32185139, 33169439, 32209438, 31636395, 31658756, 31586400, 23555315, 25503501, 28944238, 28528518, 26315354, 25186627, 21113654) - |
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Apr 23, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | May 12, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 05, 2016 | - - |
PALB2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 22, 2024 | The PALB2 c.23C>T variant is predicted to result in the amino acid substitution p.Pro8Leu. This variant has been reported in individuals with breast and colorectal cancer; however, a causative association has not been established (Ding et al. 2011. PubMed ID: 21113654; Tung et al. 2014. PubMed ID: 25186627, Supplemental Table 2; Maxwell et al. 2014. PubMed ID: 25503501, Supplemental Table 1; Cock-Rada et al. 2018. PubMed ID: 28528518, Table 2; DeRycke et al. 2017. PubMed ID: 28944238, Supplemental Table S2). Functional studies of this variant are conflicting, with some indicating similar function to wild type protein (Rodrigue et al. 2019. PubMed ID: 31586400). This variant is reported in 0.13% of alleles in individuals of African descent in gnomAD. ClinVar classifications range from benign to uncertain, with a consensus of recent classifications pointing toward likely benign (https://www.ncbi.nlm.nih.gov/clinvar/variation/126652/). Although we suspect this alteration is more likely benign, at this time, the clinical significance of this variant is uncertain due to insufficient functional and genetic evidence. - |
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Apr 19, 2022 | - - |
Familial cancer of breast Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at